TORONTO – Avicanna Inc. (“Avicanna” or the “Company“) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products, is pleased to announce that the Company has entered into a master services agreement (the “Master Services Agreement”) with the University Health Network (“UHN”) for initiatives to be carried out by Dr. Peter Carlen as the principal investigator associated to epilepsy. Additionally, the firm has accomplished the technical switch and first pharmaceutical pilot manufacturing of its epilepsy drug candidate at Altea Farmaceutica S.A. (“Altea”) in Bogota, Colombia, a serious step required for the ultimate preparation for its registration and commercialization in South America.
The epilepsy analysis collaboration is lead by Dr. Peter Carlen, who’s a Senior Scientist at the Krembil Research Institute at UHN and a world-renowned researcher in the subject of epilepsy. Dr. Carlen’s laboratory might be analyzing Avicanna’s RHO Phyto and pharmaceutical cannabinoid-based merchandise (the “Products”) for his or her efficacy in the remedy of seizures. The partnership may also co-develop a excessive throughput electrophysiological testing system for the analysis of a number of cannabinoid ratios and together with customary epileptic medicine. In addition, the system will study customary anti-seizure medicine for his or her efficacy in the mannequin and decide the potential synergistic worth of adjunctive cannabinoids, and cannabinoids as monotherapy in treating seizures on this in vitro setting.
Dr. Peter Carlen commented: “The Carlen lab is very pleased to research the relationships between the premium medicinal cannabinoid products of Avicanna and their effects on epilepsy. Also, in collaboration with Avicanna, we are developing a high-throughput platform to assess these interactions. We think that medical cannabinoids will have a major impact on brain health, particularly as we gain greater understanding of their effects on brain function in health and disease.”
The companies to be carried out underneath the Master Services Agreement might be offered on an unique foundation and Dr. Carlen’s laboratory has agreed to not conduct testing on any formulations or merchandise just like the Products for a interval of two (2) years. All mental property created underneath the Master Services Agreement will stay the sole property of Avicanna. The analysis collaboration is additional expanded to incorporate electrophysiological research of medical cannabinoids on 3D human cerebral organoids and neuroglial cultures with the help of a two-year Mitacs Accelerate program grant.
Avicanna additionally accomplished its first pharmaceutical stage manufacturing of its first epilepsy drug candidate underneath GMP and ICH pointers that are vital for sanitary drug registration. The formulation developed by Avicanna contains energetic pharmaceutical substances that are cannabinoids produced by Avicanna’s subsidiary Santa Marta Golden Hemp S.A.S. The ultimate GMP manufacturing happened at Avicanna’s unique manufacturing companion’s, Altea’s, facility in Bogota, which is a Health Canada and ANVISA (Brazil) authorized GMP facility. The completion of this pharmaceutical manufacturing now permits Avicanna to proceed with drug registrations for epilepsy throughout a number of markets in South America together with Colombia and Brazil.
Aras Azadian, CEO of Avicanna, commented: “We are pleased to demonstrate our dedication to world-class research and to take this stride in our epilepsy research program with a leading Canadian research institute and Dr. Carlen. This multi-level partnership will help to further study our current medical cannabis and pharmaceutical products, and will support the development and increase the depth of our pharmaceutical pipeline. Additionally, the completion of our first pharmaceutical production marks a milestone event in our drug development plans and highlights our capabilities to scale our drug formulations from bench top to industrial manufacturing.”
About the Krembil Research Institute at UHN
The Krembil Research Institute at Toronto Western Hospital at UHN is dwelling to one among the world’s largest and most complete groups of physicians and scientists uniquely working hand-in-hand to forestall and confront issues of the mind and backbone. One in three Canadians will expertise a brain-related situation resembling Parkinson’s, Alzheimer’s or Stroke of their lifetime. Through state-of-the-art affected person care and superior analysis, we’re working relentlessly towards discovering new therapies and cures.
Mitacs is a not-for-profit group that fosters development and innovation in Canada by fixing enterprise challenges with analysis options from tutorial establishments. Mitacs is funded by the Government of Canada, the Government of Alberta, the Government of British Columbia, Research Manitoba, the Government of New Brunswick, the Government of Newfoundland and Labrador, the Government of Nova Scotia, the Government of Ontario, Innovation PEI, the Government of Quebec, and the Government of Saskatchewan.
About Avicanna Inc.
Avicanna is a diversified and vertically built-in Canadian biopharmaceutical firm centered on the analysis, growth, and commercialization of plant-derived cannabinoid-based merchandise for the international client, medical, and pharmaceutical market segments.
Avicanna is a longtime chief in cannabinoid analysis and growth, which it primarily conducts at its R&D headquarters in the Johnson & Johnson Innovation Centre, JLABS @ Toronto, Canada and in collaboration with main Canadian tutorial and medical establishments. In addition to its creating pharmaceutical pipeline, Avicanna’s staff of specialists have developed and commercialized a number of business main product strains, together with: Pura Earth™ or Pura H&W™: a complicated and clinically examined line of CBD client derma-cosmetic merchandise; and, RHO Phyto™: a complicated line of medical hashish merchandise containing various ratios of CBD and THC presently obtainable nation-wide throughout Canada in partnership with Medical Cannabis by Shoppers™, a subsidiary of Shoppers Drug Mart. RHO Phyto is the first strictly medical formulary of superior “Cannabis 2.0” merchandise, containing oils, sprays, capsules, lotions, and gels, all 2 developed with scientific rigour, manufactured underneath GMP requirements and supported by pre-clinical knowledge.
With ongoing scientific trials on its derma-cosmetic (branded as Pura Earth or Pura H&W), medical hashish (branded as RHO Phyto) and a pipeline of pharmaceutical merchandise, Avicanna’s dedication to researching the essential function that cannabinoids play in an more and more wider scope of merchandise has been at the core of the Company’s imaginative and prescient since its inception. Furthermore, Avicanna’s dedication to training is demonstrated via its annual medical symposium, the Avicanna Academy instructional platform, and the My Cannabis Clinic affected person program via its subsidiary firm.
Avicanna manages its personal provide chain together with cultivation and extraction via its two majority-owned subsidiaries, Sativa Nativa S.A.S. and Santa Marta Golden Hemp S.A.S., each positioned in Santa Marta, Colombia. Through these sustainable, economical, and industrial scale subsidiaries, Avicanna cultivates, processes, and commercializes a variety of hashish and hemp cultivars dominant in CBD, CBG, THC, and different cannabinoids to be used as energetic pharmaceutical substances. Avicanna’s Avesta Genetica program focuses on the growth and optimization of uncommon cultivars for business manufacturing alongside with feminized seeds for international export. In June 2020, Avicanna made historical past with a cargo of hemp seeds to the United States of America by finishing the first ever export of hemp seeds from Colombia.